Itacitinib in Advanced Hepatocellular Carcinoma

Sponsor
Imperial College London
Study ID
NCT04358185
Phase
PHASE1
Status
Completed

Conditions

  • Advanced Hepatocellular Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Itacitinib — DRUG
    Novel and small molecule selective inhibitor of JAK1

Study Details

This research will assess the effects of Itacitinib as a second line treatment for patients with advanced inflammatory hepatocellular carcinoma (HCC), a type of liver cancer. Itacinib is a protein inhibitor of the tyrosine kinase, JAK1, which is believed to enable cancer cells to metastasise to other parts of the body.

Key Dates

Start date
Dec 3, 2018
Status verified
Apr 2026
Primary completion
Apr 7, 2023
Completion
Apr 7, 2023

Study Design

Enrollment
19 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Itacitinib
    Itacitinib (INCB039110) - novel and small molecule selective inhibitor of JAK1

Primary Outcome Measure

To Assess the Safety and Tolerability of Itacitinib in Patients With HCC: Adverse Events [ Time Frame: Throughout study completion, up to 1 year ]

Related Studies